In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, Kimberly-Clark’s $40 billion Kenvue deal, and more.
ByAmy Feldman,
Forbes Staff
andAlex Knapp,
Forbes Staff.
In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, Kimberly-Clark’s $40 billion Kenvue deal, and more. To get it in your inbox, subscribe here.
Pfizer beats out Novo Nordisk in bidding for obesity drugmaker Metsera | Fortune
Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
Metsera accepts Pfizer's $10 billion bid in ongoing M&A battle
Novo Nordisk again raises bid in battle for obesity start-up Metsera
Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid
Pharmaindustrie: Bieterschlacht um Metsera – Pfizer zieht mit Novo gleich
Battle for obesity biotech Metsera heats up as Pfizer sues to block rival bid
US regulator warns Novo Nordisk’s Metsera offer ‘may violate’ antitrust law
Novo Nordisk sale a Copenaghen, si ritira da gara miliardaria per Metsera
Pfizer and Novo Nordisk sweeten offers for Metsera as bidding war intensifies
